Intersect ENT, Inc. (XENT)
| Market Cap | 802.92M |
| Revenue (ttm) | 84.08M |
| Net Income (ttm) | -60.08M |
| Shares Out | 32.70M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $23.67 |
| Previous Close | $24.21 |
| Change ($) | -0.54 |
| Change (%) | -2.23% |
| Day's Open | 24.31 |
| Day's Range | 23.56 - 24.35 |
| Day's Volume | 77,349 |
| 52-Week Range | 5.97 - 26.98 |
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announce...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate in Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces New Appointments to Executive Leadership Team
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that management ...
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
Intersect ENT, Inc.'s (XENT) CEO Tom West on Q3 2020 Results - Earnings Call Transcript
Intersect ENT (XENT) delivered earnings and revenue surprises of 22.73% and 0.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Third Quarter 2020 Financial Results
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Third Quarter 2020 Financial Results
MENLO PARK, Calif. & BERLIN--(BUSINESS WIRE)--Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies
MENLO PARK, Calif. and BERLIN--(BUSINESS WIRE)--Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
Intersect ENT, Inc. (XENT) CEO Thomas West on Q2 2020 Results - Earnings Call Transcript
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
Intersect ENT (XENT) delivered earnings and revenue surprises of -30.00% and 24.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Second Quarter 2020 Financial Results
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Second Quarter 2020 Financial Results
Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.
During a period like the COVID-19 pandemic, there are at least two reasons to find an acquisition or a merger.
Shares of Intersect ENT Inc (NASDAQ: XENT), a manufacturer of sinus implants for delivering targeted therapy to the ear, nose and throat, are skyrocketing to their best level since mid-March f...
Investors reacted enthusiastically to a reported acquisition offer from Medtronic.
Sources confirmed late on Tuesday that Medtronic (NYSE: MDT) is interested in acquiring Intersect ENT (NASDAQ: XENT) and has already forwarded its offer to the medical device manufacturer. The...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results...
This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.
Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.
Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2020 Results - Earnings Call Transcript
Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Intersect ENT (NASDAQ:XENT) were unchanged at $13.49 after the company reported Q1 results.
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.
Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.
Intersect ENT (XENT) CEO Tom West on Q4 2019 Results - Earnings Call Transcript
Intersect ENT (XENT) delivered earnings and revenue surprises of 28.57% and 2.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
About XENT
Intersect ENT, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office ... [Read more...]
| Industry Medical Devices | IPO Date Jul 24, 2014 |
| CEO Thomas West | Employees 402 |
| Stock Exchange NASDAQ | Ticker Symbol XENT |
Financial Performance
In 2019, Intersect ENT's revenue was $109.14 million, an increase of 0.62% compared to the previous year's $108.47 million. Losses were -$42.99 million, 87.6% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for Intersect ENT stock is "Buy." The 12-month stock price forecast is 23.00, which is a decrease of -2.83% from the latest price.